Engdahl E, et al. Serological response against HHV-6A is associated with increased risk for multiple sclerosis. Abstract 222. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Dabrafenib plus trametinib bij BRAFV600E-gemuteerd laag- en hooggradig glioom
feb 2022 | Neuro-oncologie